Press Release Archive
April 4, 2005
April 4, 2005 PDF Version (6.5kb)
PHASE I CLINICAL TRIAL FOR ADVANCED COLON AND PANCREATIC CANCER OPENS IN NEW YORK USING REXIN-G™, THE WORLD'S FIRST TUMOR-TARGETED GENE DELIVERY VECTOR
LOS ANGELES, California, April 4, 2005 - Epeius Biotechnologies Corporation, announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer. Six out of six initial patients with advanced pancreatic cancer responded favorably to Rexin-G, as evidenced by significant shrinkage and/or disappearance of metastatic tumor nodules, or stabilization of disease, relief from pain, weight gain and extension of over-all survival time, without experiencing the side effects generally associated with standard chemotherapy. Clinical trials of Rexin-G have now been expanded to include patients with colorectal cancer that has spread to the liver.
Epeius Biotechnologies Corporation recently secured exclusive licensing rights to its Pathotropic (disease-seeking) targeting platform, including the FDA-approved Targeted Delivery System (TDS) that enables its lead product, Rexin-G™, to seek and destroy metastatic tumors. Following the success of "compassionate use" clinical trials using Rexin-G™ for metastatic pancreatic cancer, Epeius Biotechnologies has completed the transition from an academic start-up to a specialty pharmaceutical company, and has gained the financial support needed to expand the scope of its landmark clinical trials in the United States. In a statement to the press, Dr. Frederick Hall, President and CEO of Epeius said that "we are now in excellent position to complete our mission: to develop our business plan in an exemplary manner, and to commercialize our high-value lead product for the benefit of cancer patients worldwide."
MEDIA CONTACT:
Dr. Frederick L. Hall
President and CEO
Phone: 626-441-6695
Fax: 626-441-6692
Email: info@epeiusbiotech.com
You must have Adobe Acrobat Reader to view PDF files. You may download it for free by clicking here.